Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY14 | Q15391 | 4/20 | 0.53 |
| ▸ | TSPO | P30536 | 2/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.52 |
| ▸ | PPARD | Q03181 | 2/20 | 0.48 |
| ▸ | HRH1 | P35367 | 1/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.43 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.43 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.43 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.43 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.42 |
| ▸ | RARB | P10826 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6034453 | 0.97 | P2RY14 (0.52) | P2RY14TSPOCYP2C9TMEM97SIGMAR1 | |
| SCHEMBL6035663 | 0.89 | P2RY14 (0.49) | P2RY14TSPOCYP2C9TMEM97SIGMAR1 | |
| SCHEMBL6035653 | 0.88 | PPARD (0.50) | P2RY14TSPOCYP2C9TMEM97SIGMAR1 | |
| SCHEMBL6034613 | 0.87 | FFAR1 (0.58) | PPARDFFAR1 | |
| SCHEMBL14269432 | 0.85 | PPARD (0.45) | P2RY14TSPOCYP2C9TMEM97SIGMAR1 | |
| SCHEMBL6034590 | 0.85 | PPARD (0.49) | P2RY14TSPOCYP2C9TMEM97SIGMAR1 | |
| SCHEMBL6035565 | 0.84 | FFAR1 (0.57) | PPARDFFAR1 | |
| SCHEMBL6035531 | 0.83 | PPARA (0.54) | PPARD | |
| SCHEMBL6034580 | 0.81 | PPARD (0.48) | P2RY14TSPOCYP2C9TMEM97SIGMAR1 | |
| SCHEMBL6035641 | 0.81 | PPARD (0.47) | P2RY14TSPOCYP2C9TMEM97SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060148858-A1 | 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148858-A1 | 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity | GPR119, SLC5A1, CYP4B1 | P2RY14 3559/4885TSPO 1258/4885CYP2C9 161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.